Abstract
(R)-N-(2-Heptyl)-N-methylpropargylamine (R-2HMP) is a monoamine oxidase inhibitor and putative antiapoptotic agent analogous to (R)-deprenyl. In the rat, the major amine metabolites of R-2HMP have been identified as (R)-N-2-heptylmethylamine (R-2HMA), (R)-N-2-heptylpropargylamine (R-2HPA), and (R)-2-heptylamine (R-2HA). After R-2HMP was administered s.c. to male Wistar rats, it was observed that the greatest concentration was of the original drug followed in decreasing order byR-2HMA, R-2HPA, and R-2HA in brain, liver, and plasma at all times after administration. The greatest concentrations of the three metabolites were found in brain followed by liver and plasma, and the peak concentrations occurred between 15 and 30 min after administration. After oral administration, the liver contained the greatest concentrations of drug and metabolites, and, again, the peak concentrations occurred at about 15 min. In all cases, depropargylation appears to occur at a faster rate than demethylation. After s.c. administration, R-2HMP and its metabolites exhibited biexponential redistribution and elimination losses. Half-lives of the compounds in brain for the redistribution phase were: R-2HMP, 10 min;R-2HMA, 11 min; R-2HPA, 16 min; andR-2HA, 15 min.
Footnotes
-
Send reprint requests to: D.A. Durden, Neuropsychiatry Research Unit, University of Saskatchewan, 103 Wiggins Rd., Saskatoon, SK, S7N 5E4, Canada. E-mail: david.durden{at}usask.ca
-
↵1 Present address: Agriculture and Agri-Foods Canada, 107 Science Place, Saskatoon, SK, S7N 0X2.
- Abbreviations used are::
- R-2HMP
- (R)-N-(2-heptyl)-N-methylpropargylamine
- R-2HMA
- (R)-N-2-heptylmethylamine
- R-2HPA
- (R)-N-2-heptylpropargylamine
- R-2HA
- (R)-2-heptylamine
- MPA
- methylpropargylamine
- TFEOH
- trifluoroethanol
- PFB
- pentafluorobenzoyl
- PFB-Cl
- pentafluorobenzoyl chloride
- RBC
- red blood cells
- GC
- gas chromatography
- MS
- mass spectrometry
- EI
- electron impact
- MOR
- method of residuals
- NLR
- nonlinear least-squares regression
- AUC
- area under the curve
- MAO
- monoamine oxidase
- 2HA-D5
- 1,1,1,3,3-pentadeutero-2-heptylamine
- 2HMA-D3
- N-trideuteromethyl-2-heptylamine
- 2HMA-D5
- N-methyl-1,1,1,3,3,-pentadeutero-2-heptylamine
- 2HMA-D8
- N-trideuteromethyl-1,1,1,3,3,-pentadeutero-2-heptylamine
- 2HMP-D8
- N-trideutero-methyl-[1,1,1,3,3,-pentadeutero-2-heptyl]-propargylamine
- 2HPA-D5
- N-[1,1,1,3,3-pentadeutero-2-heptyl]-propargylamine
- Received May 14, 1999.
- Accepted October 12, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|